Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Follow-Up Questions
Adial Pharmaceuticals Inc のCEOは誰ですか？
Mr. Cary Claiborne は Adial Pharmaceuticals Inc の President で、2021 から在籍しています。
ADIL の株価パフォーマンスは？
ADIL の現在の価格は $0.3649 で、最終取引日から 0.63% increased 変動しました。
Adial Pharmaceuticals Inc の主な事業テーマや業界は？
Adial Pharmaceuticals Inc は Pharmaceuticals 業界、セクターは Health Care に属しています。
